Related Experiment Video
Updated: Feb 9, 2026

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice
Published on: September 26, 2018
Mineralocorticoid receptor signaling affects therapeutic effect of enzalutamide
Masaki Shiota1, Naohiro Fujimoto2, Katuyoshi Higashijima2
1Department of Urology,, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Background:
Corticosteroids play important roles in prostate cancer therapeutics. However, their role when combined with enzalutamide remains obscure. Then, we aimed to elucidate the functional and clinical impact of corticosteroids on steroid receptors in androgen receptor (AR)-targeting therapy utilizing enzalutamide.
Methods:
The therapeutic effect was studied according to concomitant use of corticosteroids in 86 men treated with enzalutamide. The sensitivity to various agents was evaluated using cytotoxicity assays in prostate cancer cells. Gene expression levels were evaluated by quantitative real-time polymerase chain reaction in prostate cancer cells and tissues.
Results:
The therapeutic effect of enzalutamide was particularly lessened with concomitant treatment with dexamethasone. Consistently, dexamethasone increased cellular resistance to enzalutamide while prednisolone and aldosterone decreased cellular resistance to enzalutamide in prostate cancer cells. Inversely, mineralocorticoid receptor (MR) knockdown augmented the activity of AR signaling and the cellular resistance to enzalutamide.
Conclusions:
MR plays a critical role in resistance to AR-targeting therapies, which may be overcome by activation of MR signaling.
Insights
Corticosteroids impact enzalutamide treatment for prostate cancer. Dexamethasone reduces effectiveness, while mineralocorticoid receptor (MR) activation may overcome resistance to androgen receptor (AR)-targeting therapies.
Area of Science:
- Oncology
- Endocrinology
- Pharmacology
Background:
- Corticosteroids are used in prostate cancer treatment.
- Their interaction with enzalutamide, an androgen receptor (AR) targeting therapy, is not fully understood.
Purpose of the Study:
- To investigate the functional and clinical effects of corticosteroids on steroid receptors during enzalutamide treatment.
- To determine the impact of corticosteroids on AR-targeting therapy efficacy.
Main Methods:
- Studied 86 men treated with enzalutamide, analyzing concomitant corticosteroid use.
- Assessed prostate cancer cell sensitivity to agents via cytotoxicity assays.
- Evaluated gene expression using quantitative real-time polymerase chain reaction.
Main Results:
- Dexamethasone significantly reduced enzalutamide's therapeutic effect, increasing cellular resistance.
- Prednisolone and aldosterone decreased enzalutamide resistance.
- Mineralocorticoid receptor (MR) knockdown enhanced AR signaling and enzalutamide resistance.
Conclusions:
- Mineralocorticoid receptor (MR) plays a key role in resistance to AR-targeting therapies.
- Activating MR signaling could potentially overcome treatment resistance.
Related Concept Videos
Signal Sequences and Sorting Receptors
Insulin: The Receptor and Signaling Pathways
Yeast Signaling
Internal Receptors
Endocrine Signaling
Synaptic Signaling

